CX Institutional Has $682,000 Stake in Danaher Co. (NYSE:DHR)

CX Institutional lifted its stake in shares of Danaher Co. (NYSE:DHR) by 2.1% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 2,970 shares of the conglomerate’s stock after acquiring an additional 62 shares during the period. CX Institutional’s holdings in Danaher were worth $682,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Manitou Investment Management Ltd. lifted its position in shares of Danaher by 0.5% during the 4th quarter. Manitou Investment Management Ltd. now owns 92,685 shares of the conglomerate’s stock valued at $21,276,000 after acquiring an additional 481 shares during the period. Hengehold Capital Management LLC lifted its position in shares of Danaher by 30.3% during the 4th quarter. Hengehold Capital Management LLC now owns 2,340 shares of the conglomerate’s stock valued at $537,000 after acquiring an additional 544 shares during the period. True North Advisors LLC lifted its position in shares of Danaher by 70.8% during the 4th quarter. True North Advisors LLC now owns 1,720 shares of the conglomerate’s stock valued at $395,000 after acquiring an additional 713 shares during the period. Janney Montgomery Scott LLC lifted its position in shares of Danaher by 1.7% during the 4th quarter. Janney Montgomery Scott LLC now owns 184,484 shares of the conglomerate’s stock valued at $42,349,000 after acquiring an additional 3,161 shares during the period. Finally, Daymark Wealth Partners LLC lifted its position in shares of Danaher by 0.9% during the 4th quarter. Daymark Wealth Partners LLC now owns 17,521 shares of the conglomerate’s stock valued at $4,022,000 after acquiring an additional 155 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Evercore ISI upped their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Barclays lowered their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Raymond James lowered their price objective on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a report on Tuesday, January 21st. Finally, Robert W. Baird lowered their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Six investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $285.55.

Danaher Price Performance

NYSE DHR opened at $245.95 on Friday. The company has a market cap of $177.65 billion, a PE ratio of 46.94, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. Danaher Co. has a 52 week low of $225.42 and a 52 week high of $281.70. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 0.32. The firm’s 50-day simple moving average is $235.33 and its two-hundred day simple moving average is $253.45.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.44%. The ex-dividend date of this dividend is Friday, December 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.